Format

Send to

Choose Destination
BJU Int. 2018 Nov;122(5):909-912. doi: 10.1111/bju.14206. Epub 2018 Apr 14.

Initial series of magnetic resonance imaging (MRI)-fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA.

Author information

1
Division of Urology, Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA.
2
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
3
Department of Radiology, University of Texas Medical Branch, Galveston, TX, USA.

Abstract

OBJECTIVES:

To describe a step-by-step guide for using the first transperineal targeted prostate biopsy platform available in the USA.

PATIENTS AND METHODS:

A total of 32 men with elevated prostate-specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications.

RESULTS:

The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri-operative complications.

CONCLUSION:

These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT03044197.

KEYWORDS:

UroNav; magnetic resonance imaging; prostate biopsy; targeted; transperineal

PMID:
29569311
PMCID:
PMC6151177
[Available on 2019-11-01]
DOI:
10.1111/bju.14206
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center